Prevision Medicine

Switzerland · Healthtech

Tests living patient cancer cells against drugs and combinations to help oncologists compare treatment options.

Testing the patient’s cells

Prevision Medicine develops PrevisionOne, a laboratory platform that measures how a patient’s living cancer cells respond to treatments. Samples from blood cancers or solid-tumour biopsies are tested against more than 100 drugs and combinations.

Automated microscopy and analysis track the responses of cancer and non-cancer cells. The resulting report ranks treatment options using the observed response, adding functional evidence to the information available to the treating oncologist.

A report for clinical decisions

The company says its workflow delivers a report within three days. It works with clinical teams that need patient-specific evidence when comparing potential treatments.

Funding history

2 rounds · 0 with disclosed amounts
AnnouncedRoundAmountInvestors
Future of Health Grant Level 3 supportUndisclosedFuture of Health Grant — Participant
Future of Health Grant Level 2 supportUndisclosedFuture of Health Grant — Participant
Sourcesprevisionmedicine.com ↗